BUENOS AIRES, Argentina--(BUSINESS WIRE)--GI Dynamics, a medical device company pioneering the development of new approaches to treat obesity and metabolic disorders, today announced new data regarding the EndoBarrier™, its novel, noninvasive device currently in clinical trials to treat obesity and type 2 diabetes. New data from a multi-center, randomized clinical trial indicate that the EndoBarrier is a safe, noninvasive device with excellent short-term weight loss results in morbidly obese patients. These data showed that patients treated with the EndoBarrier lost on average, triple the weight of their diet control group. Specifically, at just 12 weeks, the device group lost 13.7 kg (30.2 lbs) versus 4.4kg (9.7 lbs) for the control group.
